To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products
Dr Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, joined Abionyx Pharma in January as new CMO and Head of Research and Development.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Rob_Scott_DesignLabSquare.jpg472420Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2024-01-31 11:06:002024-05-24 14:20:02Abionyx Pharma with new CMO and Head of R&D
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
https://european-biotechnology.com/wp-content/uploads/2024/04/RS5839_AdobeStock_106609932_1_-scaled.jpeg14402560Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2024-01-30 10:39:172024-07-08 14:56:13£26m for Cystic Fibrosis Drug Trial
AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
https://european-biotechnology.com/wp-content/uploads/2024/04/RS5822_AdobeStock_128463659-scaled.jpeg14402560Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2024-01-29 15:13:072024-07-08 14:57:59Alvotech Advances in Biosimilar Market with Successful AVT03 Study
https://european-biotechnology.com/wp-content/uploads/2024/04/tk124_Agrifish_Council_tg.jpg12801920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-01-25 13:47:352024-07-08 15:02:172:1 for new genomic techniques
Uppsala-based ScandiNova Systems AB appoints Pernilla Enkler as the new Head of Sustainability, Quality and Communication – a newly established division.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Pernilla_Enkler_ScandiNova_Group.jpg471420Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2024-01-24 11:25:002024-07-16 17:08:27Head of Sustainability, Quality and Communication
Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.
Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160914-ac-immune.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2024-01-23 07:00:002024-07-08 15:05:57Roche jumps ship on AC Immune
After the EU Parliament’s Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft law on new genomic techniques.
https://european-biotechnology.com/wp-content/uploads/2024/04/AGRI-Council.png6591074Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-01-22 09:44:482024-07-08 15:04:42Deregulation of new genomic techniques before decision
Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
Latest NewsTo improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products
Abionyx Pharma with new CMO and Head of R&D
AppointmentsDr Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, joined Abionyx Pharma in January as new CMO and Head of Research and Development.
£26m for Cystic Fibrosis Drug Trial
Latest NewsEnterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
Alvotech Advances in Biosimilar Market with Successful AVT03 Study
Latest NewsAVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
Latest NewsDanish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.
2:1 for new genomic techniques
Latest NewsFollowing the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs.
Head of Sustainability, Quality and Communication
AppointmentsUppsala-based ScandiNova Systems AB appoints Pernilla Enkler as the new Head of Sustainability, Quality and Communication – a newly established division.
Innate immunity merger raises €75m
Latest NewsForbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.
Roche jumps ship on AC Immune
Latest NewsGenentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
Deregulation of new genomic techniques before decision
Latest NewsAfter the EU Parliament’s Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft law on new genomic techniques.